Work

Safety, efficacy, and health-related quality of life (HRQoL) of the investigational single agent orteronel (ortl) in nonmetastatic castration-resistant prostate cancer (nmCRPC).

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.5076

Authors: Maha Hussain, Paul Gettys Corn, M Dror Michaelson, Hans J. Hammers, Joshi J. Alumkal, Charles J. Ryan, Justine Yang Bruce, Susan Moran, David MacLean, Shih-Yuan Lee, H. Mark Lin, Yanyan Zhu, Hongliang Shi, Peter Mortimer, Daniel J. George

Institutions: U-M Rogel Cancer Center, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, OHSU Knight Cancer Institute, UCSF Helen Diller Family Comprehensive Cancer Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Takeda Oncology (United States), Duke Medical Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2603298350

Cites:

Cited by: 4

Related to: 10